Interview with Deepak Khanna, Senior Vice President and Managing Director UK,…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
Address: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, United Kingdom
Tel: +44 (0) 1992 467272
Merck Sharp & Dohme Limited (MSD) is the UK subsidiary of Merck & Co., Inc., of Whitehouse Station, New Jersey, USA, a leading research-based pharmaceutical company that discovers, develops, manufactures and markets a wide range of innovative pharmaceutical products to improve human health.
MSD has committed substantial investment to research and manufacturing in the UK because of the unrivalled scientific excellence and skills base available here. It has two sites in the UK: headquarters and pharmaceutical research and development laboratories in Hoddesdon, Hertfordshire; and manufacturing at Cramlington in Northumberland.
x MSD employs approximately 1,400 people in the UK
x MSD’s UK headquarters are located in Hoddesdon, Hertfordshire, where the company’s sales and marketing, medical services, market research and administration functions are situated
x Pharmaceutical research and development is also located at Hoddesdon. Recent investment has established Hoddesdon as a global centre of expertise in chemistry, to serve Merck & Co., Inc.’s organic and synthetic chemistry needs
x The pharmaceutical manufacturing and supply centre in Cramlington, Northumberland, continues to lead the industry and the Merck & Co., Inc. organisation in productivity, delivering important medicines to the Merck network
x There are additional administrative offices in both London and Stockley Park
x MSD has played a key role in the development of five of Merck & Co., Inc.’s products 16 medicines are manufactured in the UK by MSD
x The UK turnover in 2007 was £382 million
x The UK Sales Force is made up of around 500 field-based employees
MSD’s mission is to provide superior medicines which enhance patients’ quality of life. Of Merck & Co., Inc.’s most popular medicines, five have been discovered and 16 are manufactured by MSD in the UK.
MSD’s product portfolio covers a range of key therapy areas including atherosclerosis and cardiovascular disease, diabetes, infectious diseases, neuroscience and ophthalmology, respiratory, bone, arthritic conditions, and vaccines.
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record. …
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019, demonstrating that cannabinoid-based medicines can be highly profitable and potentially blazing…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial asset on the market, a strong pipeline of development assets and a…
Hopes have been raised of a cure for AIDS after a patient in London became free of the HIV virus following a bone marrow transplant. Although it is not…
Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are…
The 9th February 2019 marked the launch of the European Medicines Verification System (EMVS) which will use cutting-edge technology to safeguard the medicine supply chain against fake products. Each European country…
In recent years, apocalyptic conversations around superbugs caused by antimicrobial resistance (AMR) have been on the up, but just in case we were becoming immune to these warnings, the UK has…
An unusual characteristic of the UK’s healthcare landscape is that charities fund the vast majority of medical research. According to the Association of Medical Research Charities (AMRC), in 2017, 8 million people…
The two Big Pharma giants today announced the merger between their consumer healthcare businesses, with the joint venture (JV) set to become the global market leader in over-the-counter (OTC) products…
Ian Chamberlain looks at the changing role of the pharma sales manager and the skills needed to keep up with new tech and the next generation of millennial sales reps. With…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In his second piece for PharmaBoardroom, Aditya examines the dangers of nationalism and populism for the private sector. The biggest global risk I see…
See our Cookie Privacy Policy Here